Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
115.00    3.50 (3.14%)
Bid:
112.00
Ask:
118.00
Spread: 6.00 (5.357%)
Market Cap: £69.19m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

7 Oct 2009 07:00

RNS Number : 3501A
Intercede Group PLC
07 October 2009
 



7 OCTOBER 2009

INTERCEDE GROUP plc

("Intercede" or "the Company")

Trading Update

Intercede, a leading producer of Identity and Credential Management Systems (IDCMS) software, today announces excellent progress in the six months ended 30 September 2009.

Sales for the first half of the current financial year are more than 40% higher than for the comparable period last year. The Directors are also pleased to report that the Company has strongly increased its operating profit before exceptional items during the period.

The growth in sales is especially encouraging, because it is based both on existing customers expanding deployments installed in earlier periods and on new licence sales into new markets for actual end-customer projects. As a result, we are now experiencing a return on the investment made in development and sales efforts in previous years. Our expansion into new sectors and territories is also producing a fresh and immediate stream of revenue. This is evidence of the ongoing strength and viability of Intercede's business model and of a strategy that is being successfully executed. 

Key achievements during the period include:

Maintaining and expanding existing major projects for Lockheed MartinUK Government, US Federal Government, NHS and others. 

Winning new contracts to supply MyID to customers in AustraliaAustriaCzech RepublicRomaniaSlovakiaSwitzerland and the US.

Deploying MyID systems at a major security printing and smart card manufacturer, at a major Scandinavian bank and within a European government agency.

Adding the US Social Security Administration to Intercede's Federal HSPD-12 customer list. 

Further details will be provided when Intercede announces its Interim Results for the six months ended 30 September 2009, which is expected to take place in December 2009.

The reported period includes exceptional costs for defending a previously reported patent infringement case in the US filed by ActivIdentity Corporation. Intercede's answer and counterclaims deny that its products infringe ActivIdentity's patent and allege further that this patent is invalid and unenforceable. In addition, Intercede has filed counterclaims against ActivIdentity, including alleging violations of US antitrust law. The court recently rejected ActivIdentity's challenge to Intercede's antitrust claims and one basis for a declaration of unenforceability. While the court dismissed other counterclaims alleging fraudunfair competition, and an additional basis for a declaration of unenforceability, it gave Intercede the right to re-plead those claims with more factual detail. Intercede filed its amended counterclaims on 28 September 2009. Intercede intends to pursue its defence and its counterclaims vigorously. 

Costs and cash collections have also been kept under control throughout the period, as evidenced by a half year cash balance of £3,913,00, compared to £3,711,000 at 31 March 2009 and £1,839,000 at 30 September 2008. The cash position as at 30 September 2009 is thus more than double that of a year ago, notwithstanding the legal costs incurred to date in defending the patent infringement case brought by ActivIdentity and in pursuing the Company's counterclaims against ActivIdentity. 

Richard ParrisIntercede's Chairman and Chief Executive, said:

"Our order book indicates that Intercede is on track to continue our planned growth trajectory for this year and beyond. I am delighted that our sales pipeline is stronger than ever and that a number of our existing larger projects are set to exceed expectations in terms of future growth. In particular our entry into the national identity market is proving to be particularly rewarding while our partnerships with Lockheed Martin, Thales and VeriSign are making continuing and growing contributions to operating profit."

About Intercede 

Intercede is the producer of the MyID® Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalization, issuance and management. Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 10 Federal Agencies, a programme with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

Intercede and MyID are registered trademarks or trademarks in the UK, US and/or other countries. 

For more information visit http://www.intercede.com.

ENQUIRIES

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Charles Cunningham

Tel. +44 (0)20 7600 1658

Pelham Public Relations

Archie Berens

Tel. +44 (0)20 7337 1509

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRFSMFMMSUSEFS
Date   Source Headline
17th Dec 201810:19 amRNSBoard Change
26th Nov 20187:00 amRNSHalf-year Report
22nd Oct 20187:00 amRNSGrant of Options
4th Oct 20187:00 amRNSTrading Statement
20th Sep 20187:00 amRNSResult of AGM
4th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Aug 20187:00 amRNSDirector/PDMR Shareholding
31st Jul 20187:00 amRNSDirector/PDMR Shareholding
10th Jul 20188:00 amRNSDirector/PDMR Shareholding
29th Jun 20184:59 pmRNSPDMR Shareholding
7th Jun 20187:00 amRNSFinal Results
26th Apr 20182:10 pmRNSPDMR Change
25th Apr 20187:00 amRNSDirector/PDMR Shareholding
20th Apr 201812:15 pmRNSPDMR Change
11th Apr 201811:36 amRNSHolding(s) in Company
11th Apr 20187:00 amRNSAppointment of Chief Executive
4th Apr 20187:00 amRNSReceipt of $4.0m Order/Trading Update
29th Mar 20187:00 amRNSDirectorate Change
9th Mar 20187:00 amRNSNew Contract Award
13th Feb 20187:00 amRNSNew Contract Award
4th Dec 20177:00 amRNSContract
30th Nov 20177:00 amRNSNew Contract Award
27th Nov 20177:00 amRNSHalf-year Report
6th Nov 20171:58 pmRNSTrading Update
26th Oct 20177:00 amRNSShare Award
5th Oct 20177:00 amRNSTrading Statement
13th Sep 20173:30 pmRNSResult of AGM
13th Sep 20177:00 amRNSDirectorate Change
25th Aug 20177:00 amRNSIssue of Convertible Loan Notes
1st Aug 20179:07 amRNSTotal Voting Rights
27th Jul 20177:00 amRNSShare Incentive Plan & Issue of Equity
18th Jul 20177:00 amRNSDirector/PDMR Shareholding & TVR
13th Jun 20177:00 amRNSCollaborations with VMWare and Imagination
7th Jun 201712:06 pmRNSHolding(s) in Company
7th Jun 201712:01 pmRNSHolding(s) in Company
7th Jun 20177:00 amRNSFinal Results
6th Jun 20177:00 amRNSLaunch of MyIDaaS
25th May 20177:00 amRNSSchedule 2(g) Disclosure
23rd May 20177:00 amRNSAppointment of Chief Sales Officer
17th May 20177:00 amRNSNon-Executive Director Appointment
9th May 20177:00 amRNSContract Win
8th May 20173:45 pmRNSShare Incentive Plan
8th May 20177:00 amRNSIntercede announces Secure Login for WordPress
5th Apr 20177:00 amRNSTrading Update
31st Mar 20177:00 amRNSListing of Convertible Loan Notes
20th Mar 20177:00 amRNSAppointment of VP, US Gov't & Enterprise Sales
15th Mar 20173:03 pmRNSShare Incentive Plan
9th Mar 20177:00 amRNSAppointment of Adviser
3rd Mar 20177:00 amRNSTrading Update
27th Jan 201712:15 pmRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.